AOD9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
== Process == The first step of the PEGylation is the suitable functionalization of the PEG polymer at one or both ends. PEGs that are activated at each end with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional". The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule. The overall PEGylation processes used to date for protein conjugation can be broadly classified into two types, namely a solution phase batch process and an on-column fed-batch process. The simple and commonly adopted batch process involves the mixing of reagents together in a suitable buffer solution, preferably at a temperature between 4 and 6 °C, followed by the separation and purification of the desired product using a suitable technique based on its physicochemical properties, including size exclusion chromatography (SEC), ion exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) and membranes or aqueous two-phase systems (ATPS). The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine and tyrosine.
== Function == CGRP is produced in both peripheral and central neurons. It is a potent peptide vasodilator and can function in the transmission of nociception. In the spinal cord, the function and expression of CGRP may differ depending on the location of synthesis. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and may contribute to the regeneration of nervous tissue after injury. Conversely, CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and may be linked to the transmission of pain. In the trigeminal vascular system, the cell bodies of the trigeminal ganglion are the main source of CGRP. CGRP is thought to play a role in cardiovascular homeostasis and nociception. In the heart, CGRP acts as a chronotrope by increasing heart rate. Apart from these attributes, CGRP is known to modulate the autonomic nervous system and plays a role in ingestion. CGRP has moderate effects on calcium homeostasis compared to its extensive actions in other areas, such as the autonomic nervous system.
== Research, development and products == TCI provides end-to-end services for the nutraceutical and cosmetic sectors: market analysis and concept design, ingredient sourcing and proprietary raw material development (IBD—Integrated Bioscience Design), formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for capsules, soft gels, liquids, powders, and cosmetic formulations. The company markets private-label products under group consumer channels as well as acting as a CDMO for domestic and international brands. Subsidiaries and affiliated brands include genetic testing (TCI GENE) and consumer retail channels (TCI Living), reflecting a diversification strategy across upstream R&D and downstream retail. TCI Bio conducts research in functional ingredients, metabolic health, beauty-from-within products, and gut microbiome applications. The company reports conducting human clinical studies to evaluate ingredient efficacy in areas such as metabolic health, weight management, glycemic control, skin health, and gut health. TCI employs a proprietary AI-driven ingredient discovery system it calls Bio-Resource Data Mining, described as an automated, cloud-based platform used to identify bioactive natural compounds for potential formulation development. In addition to contract manufacturing services, TCI Bio has developed proprietary nutraceutical ingredients, including:
=== Other === Escitalopram may reduce premenstrual symptoms in women with premenstrual syndrome and premenstrual dysphoric disorder. It seems to be more effective when taken continuously compared to luteal phase administration. It is also occasionally prescribed off-label for insomnia secondary to a mental disorder, and vasomotor symptoms (hot flashes) associated with menopause.
Sources: en.wikipedia.org
Peruvian diplomacy based its principles on continental solidarity (product of Pan-Americanism) and the defense of national sovereignty and integrity, especially the Amazonian ambitions of Brazilian interests and their expansionist advances, which were now related to the Argentines. Evidence of the public condemnation of Peru towards this policy of conquest, by the Brazilians and Argentines against Paraguay, was shown in an edition of the newspaper El Comercio, dated 10/8/1866, which responded to accusations of the anti-Peruvian Argentine press that there was a lack of impartiality in the country due to Peru's sympathy with Paraguay. Given this Peruvian support to Paraguayans, Argentina reacted with anti-Peruvian positions, refusing to be a country a member of the Quadruple Alliance against Spain in the War of the Chincha Islands; In addition, the diplomacy practiced by the Triple Alliance sought to separate the Pacific governments (Chile, Peru, Bolivia and Ecuador) and thus dissolve the Quadruple Alliance. Regarding possible profitable differences, Bolivia was definitely the most vulnerable country, being a priority for Argentine diplomacy. Thus, Argentine and Uruguayan agents tried to seduce the Bolivians, telling them that the scope of the quadruple alliance treaty was not justified, while there were Bolivian territorial claims against the Peruvians and Chileans that the Bolivians still feared would not be able to defend them.
=== Surgical gingivectomy === To reduce post-operative pain for the patient, the surgery should be as atraumatic as the surgeon can make it. If the procedure has been carried out carefully, the patient's post-operative pain is minimised. Pain may be experienced initially following the procedure, but this should subside within a few days and can be appropriately controlled with drugs to alleviate the pain. The patient should also be advised to avoid using the area where the surgery was performed when chewing during the initial healing stage. Adequate plaque control is important in ensuring long-term results from the procedure, and if post-operative infection control levels are maintained then the patient should be able to keep a healthy periodontium. However, the outcome of the procedure may be influenced by other general factors such as the systemic status of the patient. If patients do not maintain the appropriate oral hygiene levels and post-operative care, then it is inevitable that the disease will return. Patients may struggle with self-performed oral hygiene initially after the procedure, due to pain and discomfort, so regular visits for professional tooth cleaning are advised. Immediately after the surgery, patients are recommended to rinse with an appropriate anti-plaque agent. After the sutures are removed, the area should be irrigated and the teeth should be polished. If the area is ready for mechanical tooth brushing to begin again, gentle brushing is demonstrated to the patient using a toothbrush that has been softened in hot water.
=== Reaction to Harry Potter partnership === In August 2026, Tim Horton announced its “Back to Hogwarts with Harry Potter” campaign, with a series of themed products released to mark the 25th anniversary of the release of the first film of the Harry Potter movie franchise. The campaign received criticism from the 2SLGBTQ+ community, with Tim Horton being rebranded by online activists as "TERF-Hortons" for being perceived to be aligning themselves with J.K. Rowling's "anti-trans" views. Advocacy group Egale Canada argued that "as a brand that is synonymous with Canada, Tim Hortons and their partnerships should reflect Canada — a country that is inclusive and proud of its diversity".
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.